Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: Cingolani, Linda, Barberio, Brigida, Zingone, Fabiana, Ferronato, Antonio, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Melatti, Piera, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, D’Incà, Renata, Savarino, Edoardo Vincenzo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121777/
https://ncbi.nlm.nih.gov/pubmed/33990652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89790-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia